Stefan Verheye, department of cardiology at Middelheim Hospital, Antwerp, said: “These clinical results suggest very promising benefits for patients. We had already demonstrated that the self-expanding and disconnectable Stentys platform ensured optimal wall apposition and easy access to side branches. We can now confirm that the addition of a drug coating eliminates the need for reintervention.”

Gonzague Issenmann, co-founder and CEO of Stentys, said: “These data fortify our conviction of the indisputable superiority of Stentys self-expanding and drug-eluting stents over balloon-expandable DES for the treatment of complex cases. We are actively pursuing our clinical program, particularly in the treatment of Acute Myocardial Infarction, to also prove the superiority of the Stentys technology in this additional group of patients.”

Based in Princeton, New Jersey and Paris, Stentys announced in December 2009 that it has started enrolling patients in the randomized Apposition II clinical trial to compare the Stentys self-expanding stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth.

Source：web of PBR